Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K. Kanemura H, et al. Among authors: kaneda h. JTO Clin Res Rep. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373. eCollection 2022 Aug. JTO Clin Res Rep. 2022. PMID: 35941997 Free PMC article.
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group. Kaneda H, et al. J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c. J Thorac Oncol. 2010. PMID: 19884859 Free article. Clinical Trial.
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. Okamoto I, et al. Among authors: kaneda h. Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5. Mol Cancer Ther. 2010. PMID: 20688946 Clinical Trial.
Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K. Kudo K, et al. Among authors: kaneda h. Clin Cancer Res. 2011 Mar 15;17(6):1373-81. doi: 10.1158/1078-0432.CCR-09-2755. Epub 2010 Dec 3. Clin Cancer Res. 2011. PMID: 21131553
601 results